First-line afatinib for advanced EGFRm+ NSCLC: Analysis of...

  • Main
  • 2019 / 4
  • First-line afatinib for advanced EGFRm+ NSCLC: Analysis of...
Lung Cancer 2019 / 4

First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials

Schuler, Martin, Paz-Ares, Luis, Sequist, Lecia V., Hirsh, Vera, Lee, Ki Hyeong, Wu, Yi-Long, Lu, Shun, Zhou, Caicun, Feng, Jifeng, Ellis, Stuart H., Samuelsen, Carl H., Tang, Wenbo, Märten, Angela, E
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Journal:
Lung Cancer
DOI:
10.1016/j.lungcan.2019.04.006
Date:
April, 2019
File:
PDF, 639 KB
2019
Conversion to is in progress
Conversion to is failed